Koers Newron Pharmaceuticals SpA CBOE EUROPE EQUITIES
Aandelen
0QOI
IT0004147952
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- CHF | - |
|
Omzet 2024 * | 36,98 mln. 39,69 mln. 35,89 mln. | Omzet 2025 * | 27,02 mln. 29 mln. 26,22 mln. | Marktkapitalisatie | 170 mln. 182 mln. 165 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 15 mln. 16,1 mln. 14,56 mln. | Nettowinst (verlies) 2025 * | 5 mln. 5,37 mln. 4,85 mln. | EV/omzet 2024 * | 5,19 x |
Nettoschuld 2024 * | 22,05 mln. 23,67 mln. 21,4 mln. | Nettoliquiditeiten 2025 * | 7 mln. 7,51 mln. 6,79 mln. | EV/omzet 2025 * | 6,03 x |
K/w-verhouding 2024 * |
10,9
x | K/w-verhouding 2025 * |
31,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,57% |
Recentste transcriptie over Newron Pharmaceuticals SpA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 15-05-12 |
Luca Benatti
FOU | Founder | 63 | 01-01-98 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-01-02 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 78 | 01-01-08 | |
Luca Benatti
FOU | Founder | 63 | 01-01-98 |
Ulrich Köstlin
CHM | Chairman | 71 | 01-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,13% | 39,05 mld. | |
-10,43% | 33,74 mld. | |
+79,21% | 28,54 mld. | |
-14,82% | 15,59 mld. | |
-3,06% | 13,69 mld. | |
-12,76% | 11,44 mld. | |
+181,73% | 10,66 mld. | |
-53,92% | 9,27 mld. | |
+5,69% | 9,13 mld. |
- Beurs
- Aandelen
- Koers NWRN
- Koers 0QOI